New drug combo takes on tough tumors

NCT ID NCT06462794

Recruiting now Disease control Sponsor: CytomX Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CX-801 (an investigational drug) and pembrolizumab (Keytruda)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 121 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START Dallas Fort Worth, LLC
RECRUITING

Fort Worth, Texas, 76104, United States
The Melanoma and Skin Cancer Institute
RECRUITING

Englewood, Colorado, 80113, United States
University of Pittsburgh Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.